Infection Prevention By Design

ChronoFlex C® with BioGUARD™ Technology

First and only catheter shown to 
Inhibit Bacterial Attachment (in vitro)¹ & 
Resist Thrombus Formation (in vivo)² Where it Matters Most

TRUST POWERWAND

BioGUARD™ TECHNOLOGY

TRUST BioGUARD

access scientific
1. Proven in vitro to significantly (p=0.0133) inhibit bacterial attachment and biofilm formation† as compared with a commonly used polyurethane catheter*.

2. The POWERWAND is proven in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein. Based on canine jugular vein thromboresistance study, correlations to clinical applications has not been ascertained.


* PowerGlide® (CR Bard, Salt Lake City, UT) - a registered trademark of C.R. Bard.
† Data on file.
‡ Data on file.

Virtually ALL device-related bloodstream infections are biofilm infections. ChronoFlex C® with BioGUARD™ Technology exhibits a 70% reduction in bacterial attachment and biofilm formation.

Thromboresistant²

ChronoFlex C® with BioGUARD™ Technology is shown (in vivo) to be thromboresistant on the surface of the catheter and on the wall of the blood vessel.

ChronoFlex C® with BioGUARD™ Technology is neither coated nor impregnated with additives.

Over 35,000 catheter-days (and counting) with ZERO BSIs* and the highest completion of therapy (less than 2% thrombosis†) compared to any catheter in its class.